These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 27216573)

  • 1. KCNQ channel openers reverse depressive symptoms via an active resilience mechanism.
    Friedman AK; Juarez B; Ku SM; Zhang H; Calizo RC; Walsh JJ; Chaudhury D; Zhang S; Hawkins A; Dietz DM; Murrough JW; Ribadeneira M; Wong EH; Neve RL; Han MH
    Nat Commun; 2016 May; 7():11671. PubMed ID: 27216573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Potential of KCNQ Potassium Channel Openers as Novel Antidepressants.
    Costi S; Han MH; Murrough JW
    CNS Drugs; 2022 Mar; 36(3):207-216. PubMed ID: 35258812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence determinants of subtype-specific actions of KCNQ channel openers.
    Wang AW; Yang R; Kurata HT
    J Physiol; 2017 Feb; 595(3):663-676. PubMed ID: 27506413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroscience. Jump-starting natural resilience reverses stress susceptibility.
    Friedman A
    Science; 2014 Oct; 346(6209):555. PubMed ID: 25359955
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder.
    Tan A; Costi S; Morris LS; Van Dam NT; Kautz M; Whitton AE; Friedman AK; Collins KA; Ahle G; Chadha N; Do B; Pizzagalli DA; Iosifescu DV; Nestler EJ; Han MH; Murrough JW
    Mol Psychiatry; 2020 Jun; 25(6):1323-1333. PubMed ID: 30385872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α
    Zhang H; Chaudhury D; Nectow AR; Friedman AK; Zhang S; Juarez B; Liu H; Pfau ML; Aleyasin H; Jiang C; Crumiller M; Calipari ES; Ku SM; Morel C; Tzavaras N; Montgomery SE; He M; Salton SR; Russo SJ; Nestler EJ; Friedman JM; Cao JL; Han MH
    Biol Psychiatry; 2019 Feb; 85(3):226-236. PubMed ID: 30336931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial.
    Costi S; Morris LS; Kirkwood KA; Hoch M; Corniquel M; Vo-Le B; Iqbal T; Chadha N; Pizzagalli DA; Whitton A; Bevilacqua L; Jha MK; Ursu S; Swann AC; Collins KA; Salas R; Bagiella E; Parides MK; Stern ER; Iosifescu DV; Han MH; Mathew SJ; Murrough JW
    Am J Psychiatry; 2021 May; 178(5):437-446. PubMed ID: 33653118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of KCNQ Channels Suppresses Spontaneous Activity in Dorsal Root Ganglion Neurons and Reduces Chronic Pain after Spinal Cord Injury.
    Wu Z; Li L; Xie F; Du J; Zuo Y; Frost JA; Carlton SM; Walters ET; Yang Q
    J Neurotrauma; 2017 Mar; 34(6):1260-1270. PubMed ID: 28073317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing depression mechanisms in midbrain dopamine neurons achieves homeostatic resilience.
    Friedman AK; Walsh JJ; Juarez B; Ku SM; Chaudhury D; Wang J; Li X; Dietz DM; Pan N; Vialou VF; Neve RL; Yue Z; Han MH
    Science; 2014 Apr; 344(6181):313-9. PubMed ID: 24744379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective targeting of M-type potassium K
    Li L; Sun H; Ding J; Niu C; Su M; Zhang L; Li Y; Wang C; Gamper N; Du X; Zhang H
    Br J Pharmacol; 2017 Dec; 174(23):4277-4294. PubMed ID: 28885682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine.
    Hansen HH; Andreasen JT; Weikop P; Mirza N; Scheel-Krüger J; Mikkelsen JD
    Eur J Pharmacol; 2007 Sep; 570(1-3):77-88. PubMed ID: 17628530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat.
    Hansen HH; Ebbesen C; Mathiesen C; Weikop P; Rønn LC; Waroux O; Scuvée-Moreau J; Seutin V; Mikkelsen JD
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1006-19. PubMed ID: 16775195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.
    Padilla K; Wickenden AD; Gerlach AC; McCormack K
    Neurosci Lett; 2009 Nov; 465(2):138-42. PubMed ID: 19733209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels.
    Zhang D; Thimmapaya R; Zhang XF; Anderson DJ; Baranowski JL; Scanio M; Perez-Medrano A; Peddi S; Wang Z; Patel JR; DeGoey DA; Gopalakrishnan M; Honore P; Yao BB; Surowy CS
    J Neurosci Methods; 2011 Aug; 200(1):54-62. PubMed ID: 21723881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resilience to chronic stress is mediated by noradrenergic regulation of dopamine neurons.
    Isingrini E; Perret L; Rainer Q; Amilhon B; Guma E; Tanti A; Martin G; Robinson J; Moquin L; Marti F; Mechawar N; Williams S; Gratton A; Giros B
    Nat Neurosci; 2016 Apr; 19(4):560-3. PubMed ID: 26878672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic-like effect of retigabine [N-(2-Amino-4-(fluorobenzylamino)-phenyl)carbamic acid ester], a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission.
    Sotty F; Damgaard T; Montezinho LP; Mørk A; Olsen CK; Bundgaard C; Husum H
    J Pharmacol Exp Ther; 2009 Mar; 328(3):951-62. PubMed ID: 19098162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation.
    Dost R; Rostock A; Rundfeldt C
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Apr; 369(4):382-90. PubMed ID: 15007538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kv7 channels in the nucleus accumbens are altered by chronic drinking and are targets for reducing alcohol consumption.
    McGuier NS; Griffin WC; Gass JT; Padula AE; Chesler EJ; Mulholland PJ
    Addict Biol; 2016 Nov; 21(6):1097-1112. PubMed ID: 26104325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data.
    Orhan G; Wuttke TV; Nies AT; Schwab M; Lerche H
    Expert Opin Pharmacother; 2012 Aug; 13(12):1807-16. PubMed ID: 22783830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
    Gunthorpe MJ; Large CH; Sankar R
    Epilepsia; 2012 Mar; 53(3):412-24. PubMed ID: 22220513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.